pipeline-prospector-insert
X

Find Novel Dermatology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): WEG232

            Therapeutic Area: Dermatology Product Name: WEG232

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: George Washington University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 16, 2020

            Details:

            Hoth Therapeutics has expanded its research agreement with the George Washington University to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VNLG 152

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 03, 2020

            Details:

            Management provides pipeline update for assets including BioLexa Platform (Dermatological), VNLG-152 (Dermatological), WEG-232 (Dermatological), VaxCelerate (COVID-19), Novel Peptide Therapeutic (COVID-19), AEA-loaded Z-pods™ (Lupus), Exon Skipping Approach (Allergic Disease).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 03, 2020

            Details:

            Kymera is developing potent and selective orally administered IRAK4 degraders for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven autoimmune and autoinflammatory diseases.

            Chelexa Biosciences

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antimicrobial therapy

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hoth Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 18, 2020

            Details:

            Hoth Therapeutics has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, antimicrobial therapy focused on treating atopic dermatitis. The agreement is an extension to the previously executed sublicense agreement with Chelexa Biosciences.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tetrahydrocannabinol,Cannabidiol

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 16, 2020

            Details:

            PP004 will be used for management of pain and itch in EB, symptoms that, despite a range of current treatment strategies, significantly affect the quality of life in EB patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Retinamide

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 09, 2020

            Details:

            As part of the next phase of this study, the assay will be tested to explore whether VNLG-152 is capable of blocking this inflammatory response.

            Isoprene Pharmaceuticals

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Retinamide

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hoth Therapeutics

            Deal Size: $0.1 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 30, 2020

            Details:

            Through this agreement, Hoth Therapeutics acquires the full licensing rights of VNLG-152 novel retinamides for the treatment of dermatological diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): WEG232

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 19, 2020

            Details:

            WEG232 topical treatment showed a 71% reduction in SD-Rats with erlotinib-induced facial rash/hair loss.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antimicrobial therapy

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 21, 2020

            Details:

            The BioLexa Platform is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach treating atopic dermatitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Staphylococcus epidermidis strain

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 10, 2020

            Details:

            Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future License Agreement.